3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the past 15 years there has been an exponential increase in the number of prescriptions for lipid-lowering drugs. Uncertainties remain about the long-term impact of these medications on cancer, which is particularly bothersome given that the duration of these treatments may extend for several decades. OBJECTIVE: To explore the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and cancer incidence. METHODS: Using the administrative health databases of the Régie de l'Assurance-Maladie du Québec we performed a nested case-control study. We selected a cohort of 6721 beneficiaries of the health care plan of Quebec who were free of cancer for at least 1 year at cohort entry, 65 years and older, and treated with lipid-modifying agents. Cohort members were selected between 1988 and 1994 and were followed up for a median period of 2.7 years. From the cohort, 542 cases of first malignant neoplasm were identified, and 5420 controls were randomly selected. Users of HMG-CoA reductase inhibitors were compared with users of bile acid-binding resins as to their risk of cancer. Specific cancer sites were also considered. RESULTS: Users of HMG-CoA reductase inhibitors were found to be 28% less likely than users of bile acid-binding resins to be diagnosed as having any cancer (rate ratio, 0.72; 95% confidence interval, 0.57-0.92). All specific cancer sites under study were found to be not or inversely associated with the use of HMG-CoA reductase inhibitors. CONCLUSION: The results of our study provide some degree of reassurance about the safety of HMG-CoA reductase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A chronic disease score from automated pharmacy data
Von Korff, M., Wagner, E. H., & Saunders, K. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 961
International Classification of Diseases, Ninth Revision
National Cancer Institute (2020) · Definitions · doi:10.32388/bd1nux · Cited by 888
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D., Blackburn, H., Higgins, M., Reed, D., Iso, H., McMillan, G., Neaton, J., Nelson, J., Potter, J., & Rifkind, B. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Persistence of Use of Lipid-Lowering Medications: A Cross-National Study
Avorn, J., Monette, J., Lacour, A., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 634
Self-citationTamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
HEBERT, P. R., GAZIANO, J. M., CHAN, K. S., & HENNEKENS, C. H. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00060 · Cited by 506
Biased Selection of Controls for Case-Control Analyses of Cohort Studies
Lubin, J. H., & Gail, M. H. (1984) · Biometrics · doi:10.2307/2530744 · Cited by 414
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Inhaled and Nasal Glucocorticoids and the Risks of Ocular Hypertension or Open-angle Glaucoma
Garbe, E. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540330044033 · Cited by 350
Cited by
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 578
The Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, A. C. G., Richel, D. J., & Guchelaar, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 528
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Statin Drugs and Risk of Advanced Prostate Cancer
Platz, E. A., Leitzmann, M. F., Visvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj499 · Cited by 406
Breast Cancer Growth Prevention by Statins
Campbell, M. J., Esserman, L. J., Zhou, Y., Shoemaker, M., Lobo, M., Borman, E., Baehner, F., Kumar, A. S., Adduci, K., Marx, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4061 · Cited by 348
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Role of Cholesterol in the Development and Progression of Breast Cancer
Llaverias, G., Danilo, C., Mercier, I., Daumer, K., Capozza, F., Williams, T. M., Sotgia, F., Lisanti, M. P., & Frank, P. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.005 · Cited by 327
The Role of the Perioperative Period in Recurrence After Cancer Surgery
Gottschalk, A., Sharma, S., Ford, J., Durieux, M. E., & Tiouririne, M. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181de0ab6 · Cited by 309
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 285
Cancer risk among statin users: A population‐based cohort study
Friis, S., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Fryzek, J. P., Dalton, S. O., Sørensen, H. T., & Olsen, J. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20758 · Cited by 275
Bérard, A., Ramos, É., Rey, É., Blais, L., St.‐André, M., & Oraichi, D. (2007) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20099 · Cited by 275
Self-citationStatin use and cancer risk: a comprehensive review
Boudreau, D. M., Yu, O., & Johnson, J. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003662620 · Cited by 274
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Cooke, J. P. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00034-5 · Cited by 266
Cholesterol and prostate cancer
Freeman, M. R., & Solomon, K. R. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10724 · Cited by 266
Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., & Sampliner, R. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.001 · Cited by 159
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr070 · Cited by 103
Metadata
- Authors
- Blais, L., Desgagné, A., & LeLorier, J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-08-14
- Volume
- 160
- Issue
- 15
- Pages
- 2363
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2065461844
- Cited by
- 326
- References
- 14
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.